A Phase 2 interventional study of botulinum toxin, Type A and Vehicle in Lateral Canthal Lines, LCL and Crow's Feet, sponsored by Eirion Therapeutics Inc.. Completed at 3 sites in United States. Open to female participants aged 25 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-07-28.
Sponsored by Eirion Therapeutics Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).
This product is being tested for its ability to reduce lateral canthal lines (LCL), also known as Crow's Feet.
Eirion Therapeutics Inc. is the lead sponsor of 7 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Vehicle, topical liniment, administered once at baseline
Biological: Vehicle
botulinum toxin, Type A, topical liniment, administered once at baseline
Biological: botulinum toxin, Type A
topical liniment
Also known as: ET-01 1610U
Vehicle Formulation
Number of Participants With a Response Defined as Change in IGA-C (Investigators Global Assessment) Score by at Least 2 Ordinals From Baseline to Week 4
Investigators Global Assessment of the Crow's Feet Wrinkle Scale where severity is scored between 0-4 (0=absent; 4=severe). Response is defined as change by at least two ordinals from Baseline to Week 4.
Time frame: Week 4
Total Number of Observations With a Response Defined as Change ≥2 in IGA-C and SSA-C Score at Any Post Baseline Visit
Total number of observations with a change in the Investigators Global Assessment on Contraction, IGA-C, and the Subject Self-Assessment on Contraction, SSA-C, using the Crow's Feet Wrinkle Scale, where severity is scored between 0-4 (0=absent; 4=severe). To count, a "responder" is defined as a change by at least two ordinals in both assessments. The observation period includes all post-baseline visits from Week 1 to Week 26.
Time frame: Week 1, 2, 4, 8,12,18, and 26
Total Number of Observations With a Response Defined as Change in SSA-C Score ≥ 2 at Any Post Baseline Visit
Total number of observations with a change in the Subject Self-Assessment on Contraction, SSA-C, using the Crow's Feet Wrinkle Scale, where severity is scored between 0-4 (0=absent; 4=severe). To count, a "responder" is defined as a change by at least two ordinals in both assessments. The observation period includes all post-baseline visits from Week 1 to Week 26.
Time frame: Week 1, 2, 4, 8,12,18, and 26
Participants were recruited from three medical centers between February 2019 and October 2019
| Milestone | Vehicle | ET-01 1610U |
|---|---|---|
| Started | 19 | 19 |
| Completed | 19 | 19 |
| Not completed | 0 | 0 |
Investigators Global Assessment of the Crow's Feet Wrinkle Scale where severity is scored between 0-4 (0=absent; 4=severe). Response is defined as change by at least two ordinals from Baseline to Week 4.
| Participants | Vehicle | ET-01 1610U |
|---|---|---|
| Number of Participants With a Response Defined as Change in IGA-C (Investigators Global Assessment) Score by at Least 2 Ordinals From Baseline to Week 4 | 3 | 1 |
Total number of observations with a change in the Investigators Global Assessment on Contraction, IGA-C, and the Subject Self-Assessment on Contraction, SSA-C, using the Crow's Feet Wrinkle Scale, where severity is scored between 0-4 (0=absent; 4=severe). To count, a "responder" is defined as a change by at least two ordinals in both assessments. The observation period includes all post-baseline visits from Week 1 to Week 26.
| Observations | Vehicle | ET-01 1610U |
|---|---|---|
| Total Number of Observations With a Response Defined as Change ≥2 in IGA-C and SSA-C Score at Any Post Baseline Visit | 8 | 12 |
Total number of observations with a change in the Subject Self-Assessment on Contraction, SSA-C, using the Crow's Feet Wrinkle Scale, where severity is scored between 0-4 (0=absent; 4=severe). To count, a "responder" is defined as a change by at least two ordinals in both assessments. The observation period includes all post-baseline visits from Week 1 to Week 26.
| Observations | Vehicle | ET-01 1610U |
|---|---|---|
| Total Number of Observations With a Response Defined as Change in SSA-C Score ≥ 2 at Any Post Baseline Visit | 15 | 20 |
Collected over 26 Weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vehicle | 0/19 (0%) | 0/19 (0%) | 6/19 (31.6%) |
| ET-01 1610U | 0/19 (0%) | 0/19 (0%) | 2/19 (10.5%) |
| Event | Vehicle | ET-01 1610U |
|---|---|---|
| Urinary Tract InfectionRenal and urinary disorders | 2/19 | 0/19 |
| Upper Respiratory Tract InfectionRespiratory, thoracic and mediastinal disorders | 0/19 | 1/19 |
| Thermal BurnSkin and subcutaneous tissue disorders | 0/19 | 1/19 |
| FolliculitisSkin and subcutaneous tissue disorders | 0/19 | 1/19 |
| Endodontic ProcedureSurgical and medical procedures | 1/19 | 0/19 |
| Oral HerpesGeneral disorders | 1/19 | 0/19 |
| NephrolithiasisRenal and urinary disorders | 1/19 | 0/19 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/19 | 0/19 |
| HordeolumEye disorders | 1/19 | 0/19 |
| NasopharyngitisRespiratory, thoracic and mediastinal disorders | 1/19 | 0/19 |
| Age, Categorical(Participants) | Vehicle | ET-01 1610U | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 19 | 19 | 38 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Vehicle | ET-01 1610U | Total |
|---|---|---|---|
| Female | 19 | 19 | 38 |
| Male | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Vehicle | ET-01 1610U | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 19 | 19 | 38 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Vehicle | ET-01 1610U | Total |
|---|---|---|---|
| United States | 19 | 19 | 38 |
| IGA-C(units on a scale) | Vehicle | ET-01 1610U | Total |
|---|---|---|---|
| Mean | 3.4 ± 0.5 | 3.4 ± 0.5 | 3.4 ± 0.5 |
| SSA-C(units on a scale) | Vehicle | ET-01 1610U | Total |
|---|---|---|---|
| Mean | 3.6 ± 0.5 | 3.5 ± 0.5 | 3.6 ± 0.5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2019 to primary completion in May 2019, 2 months.
Results were first posted in Jun 2022, 3 years 1 month after primary completion. A results delay was requested in May 2020.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Botulinum toxin type A
Eirion Therapeutics Inc.